| abstract |
The present disclosure relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the method relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Hepatitis A virus cellular receptor 1, lnterleukin-l receptor-like 1, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients. |